PARP inhibitors linked to myelodysplastic syndrome, AML, meta-analysis confirms

Reuters Health - 12/01/2021 - About 1% of patients on poly(ADP-ribose) polymerase (PARP) inhibitors develop myelodysplastic syndrome and/or acute myeloid leukemia (AML), a new safety meta-analysis confirms. The median duration from starting PARP-inhibitor therapy to receiving a diagnosis of myelodysplastic syndrome or AML was about 18 months, Dr. Pierre-Marie Morice of Cancer Center Francoise Baclesse in Caen, France, and colleagues report in The Lancet Haematology. "The great clinical benefit provided by these therapies (particularly in patients with ovarian cancers) combined with their growing use in other type of cancer requires careful monitoring," Dr. Morice, the study's first author, told Reuters Health by email. The U.S. Food and Drug Administration and the European Medicines Agency approved four PARP inhibitors in 2014-2018, Dr. Morice and his team note. They may be prescribed to patients with ovarian, breast, pancreatic or prostate cancer. Adv...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 12 January, 202119 January, 2021